In September 2024, Sanofi entered an exclusive licensing agreement with Orano Med and RadioMedix to globally commercialize ...
ScienceAlert on MSN
Weight Loss Isn't Essential For Reversing Prediabetes, New Study Shows
For people with abnormally high blood sugar levels, losing weight is often proposed as the primary approach to preventing ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with type 1 diabetes. Semaglutide, the active ingredient in Ozempic, and other ...
Researchers at a Harvard Medical School laboratory are uncertain how they will continue supporting a large public genetic database after its primary source of funding expired last month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback